Subscribe to Search results

Glasgow symposium considered liver disease in haemophilia.

Published on:

US Centers for Disease Control reported three confirmed cases of people with haemophilia who had developed AIDS.

Published on:

UKHCDO meeting referred to "remote possibility" that commercial blood products were the cause of AIDS in people with haemophilia in the US.

Published on:

Dr Craske's paper on AIDS made it clear that an infectious agent was the most likely cause.

Published on:

Letter from Professor Bloom and Dr Rizza regarding administration of factor concentrates to previously untreated patients.

Published on:

The New England Journal of Medicine warned of risks of AIDS to people with haemophilia and advocated a revised approach to treatment.

Published on:

AIDS discussed at Heathrow hotel meeting of haemophilia centre directors.

Published on:

Professor Bloom reported to CDSC a "probable" case of AIDS in one of his patients.

Published on:

Special meeting of reference centre directors discussed AIDS.

Published on:

Letter from Professor Bloom and Dr Rizza set out general recommendations for treatment agreed at the 13 May 1983 special meeting.

Published on:

Professor Bloom told UKHCDO meeting that there was "no proof that commercial concentrates were the cause of AIDS"; meeting agreed that patients "should not be encouraged to go over to cryoprecipitate for home therapy".

Published on:

UKHCDO released AIDS Advisory Document.

Published on:

Five commercial Factor 8 products (Hemofil, Kryobulin, Profilate, Factorate and Koate) were granted licences in the UK.

Published on:

World in Action: Blood Money was broadcast on television in the UK.

Published on:

The Food and Drug Administration inspection regime for plasma centres commenced in the US.

Published on:

The Morbidity and Mortality Weekly Report reported that three people with haemophilia had contracted AIDS in the US.

Published on:

Alpha informed the Food and Drug Administration it would not be using plasma from hyperimmunised donors for factor concentrate manufacture.

Published on:

A memo from Dr John Hink of Cutter recorded his intention that remaining high titre plasma, dating from July 1982, would be processed in experimental products that would not be for human use.

Published on:

Pharmaceutical companies started excluding high risk donors (especially male homosexuals, intravenous drug users).

Published on:

A public meeting was held in Atlanta at the instigation of Centers for Disease Control to discuss AIDS.

Published on: